stockrow
Friday 6 November 2026
Export BBNX’s income statement to Excel — free account
Beta Bionics, Inc.
BBNX Healthcare Medical Devices
Beta Bionics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $100.3 million, up 53.9% from fiscal 2024.
- Revenue
- +30.3%
- EPS
- −58.6%
- Free cash flow
- −45.5%
Quarter to September 2026, against a year earlier
14.49
1.00
−6.46%
Follow BBNX
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | 12 | 65 | 100 | 127 | +189.1% | 126 | 186 | 285 | +41.6% | |
| Gross margin, % | — | — | — | — | — | — | — | 52.59 | 55.11 | 55.40 | 58.63 | +2.8 pt | ||||||
| EBT | — | — | — | — | — | — | — | (44) | (55) | (73) | (83) | +28.8% | ||||||
| EBT margin, % | — | — | — | — | — | — | — | (367.64) | (84.08) | (73.02) | (65.31) | +294.6 pt | ||||||
| Net income | — | — | — | — | — | — | — | (44) | (55) | (73) | (83) | +28.8% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | 2.26 | 10.23 | 2.47 | 2.73 | +4.6% | |||||
| Earnings | — | — | — | — | — | — | — | (8.31) | (8.60) | (1.81) | (1.84) | (53.3%) | ||||||
| Cash flow | — | — | — | — | — | — | — | (6.12) | (7.58) | (1.26) | (1.28) | (54.7%) | ||||||
| Capex | — | — | — | — | — | — | — | (0.07) | (11.32) | (6.96) | (6.09) | +863.2% | ||||||
| Free cash flow | — | — | — | — | — | — | — | (6.19) | (18.91) | (8.22) | (7.36) | +15.2% | ||||||
| Book value | — | — | — | — | — | — | — | (38.29) | (38.55) | 7.10 | 8.62 | n/m | ||||||
| Shares, m | — | — | — | — | — | — | — | 5 | 6 | 41 | 44 | +176.4% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | — | — | 2.42 | 2.42 | 12.32 | 5.64 | 5.7 | ||||||
| P/B | — | — | — | — | — | — | — | 0.00 | 0.00 | 4.29 | 1.79 | 1.4 | ||||||
| EV/Sales | — | — | — | — | — | — | — | 0.83 | 0.83 | 10.13 | 3.75 | 3.9 | ||||||
| EV/FCF | — | — | — | — | — | — | — | (1.04) | (1.04) | (3.05) | (1.39) | (1.7) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | (32) | (48) | (51) | (59) | +25.3% | |||||
| Capex | — | — | — | — | — | — | — | 0 | (72) | (282) | (283) | +2,562.0% | ||||||
| Free cash flow | — | — | — | — | — | — | — | (33) | (120) | (333) | (343) | +218.4% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | 93 | 112 | 237 | 260 | +59.6% | |||||
| Net debt | — | — | — | — | — | — | — | (97) | (104) | (219) | (240) | +50.5% | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | (203) | (245) | 288 | 401 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | 0.00 | (42.17) | (30.60) | (21.48) | (30.6) pt | |||||
| ROIC | — | — | — | — | — | — | — | 0.00 | 0.00 | (65.51) | (35.92) | (65.5) pt | ||||||
| ROE | — | — | — | — | — | — | — | 0.00 | 24.42 | (346.51) | (23.88) | (346.5) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 294 | 294 | 423 | — | +19.9% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.04 | 0.22 | 0.24 | — | +141.0% | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 2 Nov 2026
Beta Bionics, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| AHCO AdaptHealth Corp. | $1.0B | — (loss-making) | — (loss-making) | +10.90% (above 0%: growing) | n/m | −23.58% (below 0%: shrinking) | 15.40% | (20.91%) | Compare |
| CBLL CeriBell, Inc. | $1.0B | — (loss-making) | — (loss-making) | +29.89% (above 0%: growing) | n/m | −19.65% (below 0%: shrinking) | 89.77% | (70.03%) | Compare |
| BVS Bioventus Inc. | $899.9M | 12.3× | 17.2× | +2.73% (above 0%: growing) | +100.60% (above 0%: growing) | −31.40% (below 0%: shrinking) | 68.19% | 6.81% | Compare |
| QDEL QuidelOrtho Corporation | $880.5M | — (loss-making) | — (loss-making) | −11.57% (below 0%: shrinking) | n/m | +120.70% (above 0%: growing) | 46.79% | (1.21%) | Compare |
| BBNX Beta Bionics, Inc. | $842.1M | — (loss-making) | — (loss-making) | +30.28% (above 0%: growing) | n/m | −45.46% (below 0%: shrinking) | 57.26% | (74.94%) | |
| KIDS OrthoPediatrics Corp. | $841.3M | — (loss-making) | — (loss-making) | +18.63% (above 0%: growing) | n/m | +146.64% (above 0%: growing) | 74.28% | (5.81%) | Compare |
| VREX VAREX IMAGING | $783.0M | 34.8× | 39.2× | +3.69% (above 0%: growing) | n/m | +757.14% (above 0%: growing) | 36.44% | 10.83% | Compare |
| INMD InMode Ltd. | $771.1M | 10.7× | 11.8× | −0.01% (below 0%: shrinking) | −30.95% (below 0%: shrinking) | −12.63% (below 0%: shrinking) | 74.82% | 12.82% | Compare |
| PACB Pacific Biosciences of California, Inc. | $755.3M | — (loss-making) | — (loss-making) | +5.52% (above 0%: growing) | n/m | −101.95% (below 0%: shrinking) | 33.21% | (91.22%) | Compare |
| Median of peers | $860.9M | 12.3× | 17.2× | +4.61% | — | −16.14% | 57.49% | (3.51%) |
Pay and ownership Proxy statement filed 10 April 2026
Ownership
Directors and executive officers, together
5.30%
Entities affiliated with Zone Healthcare Holdings, LLC
9.90%
Entities affiliated with Soleus Capital Management, L.P.
5.70%
Entities affiliated with RTW Investments, LP
5.60%
Entities affiliated with Point72 Asset Management, L.P.
5.20%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement